BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2261877)

  • 1. [Alterations of c-myc and c-Ha-ras-1 oncogenes in human ovarian cancer].
    Serova OM; Nikiforova IF; Iurkova LE; Vinokurov VL; Kniazev PG
    Eksp Onkol; 1990; 12(6):47-9. PubMed ID: 2261877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frequency and rearrangements of alleles of proto-oncogene c-Ha-ras-1 and their association with development of various malignant tumors in man].
    Nikiforova IF; Serova OM; Pluzhnikova GF; Kniazev PG; Seĭts IF
    Genetika; 1990 Mar; 26(3):531-40. PubMed ID: 1972367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and rearrangements of alleles of c-Ha-ras-1 protooncogene and their correlation with the development of lung, ovarian and thyroid cancers.
    Knyazev PG; Nikiforova IF; Serova OM; Pluzhnikova GF
    Neoplasma; 1990; 37(6):647-55. PubMed ID: 1980342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
    Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
    Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
    Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA
    Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras, C-myc and C-erbB-2 oncoprotein expression in non-AIDS Mediterranean Kaposi's sarcoma.
    Spandidos DA; Kaloterakis A; Yiagnisis M; Varatsos A; Field JK
    Anticancer Res; 1990; 10(6):1619-25. PubMed ID: 1980998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes.
    Pechoux C; Chardonnet Y; Chignol MC; Noël P
    Histol Histopathol; 1994 Jan; 9(1):35-44. PubMed ID: 8003818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma.
    Barrios C; Castresana JS; Ruiz J; Kreicbergs A
    J Orthop Res; 1993 Jul; 11(4):556-63. PubMed ID: 8101872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers.
    Riou G; Barrois M; Sheng ZM; Duvillard P; Lhomme C
    Oncogene; 1988 Sep; 3(3):329-33. PubMed ID: 3060795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic alterations in the genesis and development of ovarian cancer].
    Okamoto A; Yokoyama S; Terashima Y
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amplification of proto-oncogenes C-myc, C-N-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma].
    Bian M; Fan Q; Huang S
    Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):406-9. PubMed ID: 7587576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplifications of proto-oncogenes in ovarian carcinoma.
    Bian M; Fan Q; Huang S; Ma J; Lang J
    Chin Med J (Engl); 1995 Nov; 108(11):844-8. PubMed ID: 8585978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [c-myc and c-Ha-ras proto-oncogenes in cervical cancer: prognostic value].
    Riou G; Sheng ZM; Zhou D; Lusinchi A; Le Doussal V; Barrois M
    Bull Cancer; 1990; 77(4):341-7. PubMed ID: 2191730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression and amplification of c-myc and c-Ha-ras oncogenes in pleomorphic salivary adenoma.
    Xue H; Situ ZQ; Wang CJ; Wu JZ
    Chin Med J (Engl); 1993 Jan; 106(1):22-5. PubMed ID: 8389270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
    Tanaka T; Seeger RC; Tanabe M; Hiyama E; Shimoda H; Ida N
    Cancer Detect Prev; 1994; 18(4):283-9. PubMed ID: 7982238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ontogeny of Ha-ras and c-myc mRNA levels in rabbit embryo and extraembryonic tissues by quantitative in situ hybridization.
    Martinoli MG; Lambert RD; Pothier F; Pelletier G
    Mol Reprod Dev; 1992 Jan; 31(1):1-8. PubMed ID: 1562321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of the clusterin gene by Ha-ras and c-myc oncogenes and during apoptosis.
    Klock G; Storch S; Rickert J; Gutacker C; Koch-Brandt C
    J Cell Physiol; 1998 Dec; 177(4):593-605. PubMed ID: 10092212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene patterns in breast and ovarian carcinomas.
    Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
    Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.